Stem Cell Therapy for Age-Related Macular Degeneration

What This Article Covers

Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, and researchers have spent over a decade testing whether lab-grown retinal cells derived from stem cells can replace the tissue AMD destroys. Some of that research — particularly for the “dry” form of AMD and its advanced stage, geographic atrophy — has produced genuinely encouraging early results. But no stem cell-derived product is FDA-approved for AMD today, and this is also one of the areas where unregulated clinics have caused documented, serious harm. This article lays out what legitimate trials have found, what remains unproven, and how to avoid the treatments that have hurt patients.

How It's Thought to Work

AMD damages or kills the retinal pigment epithelium (RPE), a thin layer of cells that supports and nourishes the light-sensing photoreceptors in the retina. Once RPE cells die, in geographic atrophy, they don't regenerate, and vision loss is permanent. The scientific rationale behind stem cell approaches is to grow replacement RPE cells in the lab — from human embryonic stem cells or from a patient's own reprogrammed (induced pluripotent) stem cells — and then deliver them into the retina, either as a suspension of cells or as an engineered patch, to support surviving photoreceptors and potentially slow or partially reverse damage.

What the Evidence Shows

The most credible data comes from small, carefully monitored trials, not commercial clinics. In Lineage Cell Therapeutics' OpRegen program — an embryonic stem cell-derived RPE cell suspension developed with Roche and Genentech — 36-month follow-up data presented in June 2025 showed that patients with extensive cell coverage gained a mean of about 9 letters of visual acuity, with structural retinal improvements that persisted over three years and no teratoma formation or other pathological complications reported. Separately, the London Project to Cure Blindness, published in Nature Biotechnology in 2018, surgically implanted an engineered RPE patch in two patients with wet AMD; both went from being unable to read even with glasses to reading 60–80 words per minute within a year. These are real, peer-reviewed signals worth taking seriously — though both studies involved only a handful of patients, and larger, controlled trials are still needed to confirm benefit. A current NIH-funded trial at the National Eye Institute, testing a patient-derived iPSC-RPE patch for geographic atrophy, is explicit that its primary goal is safety, not vision improvement, and states the treatment “is not expected to benefit participants' vision in a manner that would aid reading.”

Set against that legitimate research is a documented pattern of harm from clinics offering unapproved “stem cell” injections outside of any registered trial. In a widely reported 2017 New England Journal of Medicine case report, three elderly women were left legally blind after a Florida clinic injected their own fat-derived cells, mixed with platelet-rich plasma, directly into both eyes — a procedure an accompanying NEJM editorial compared to “the modern equivalent of snake oil.” The FDA has since taken enforcement action against clinics selling unapproved regenerative products and states plainly that such products “have not been approved to treat autism, macular degeneration, blindness, chronic pain, or fatigue.”

Who Might Be a Candidate

• People with geographic atrophy or wet AMD who are eligible for and enrolled in a registered clinical trial (searchable on ClinicalTrials.gov) under NIH, academic, or pharmaceutical company sponsorship
• Patients working with a retina specialist who can confirm a trial's legitimacy and monitor for complications
• No one seeking treatment outside a monitored trial — there is currently no FDA-approved stem cell therapy for AMD available to the public
• Patients should be especially wary of clinics charging out-of-pocket fees for “stem cell” eye injections, a red flag seen in documented harm cases
• Anyone considering a trial should ask specifically whether it is FDA-authorized (an Investigational New Drug application) and registered

Bottom Line

Legitimate, peer-reviewed research on stem cell-derived retinal cells for AMD is genuinely promising, with multi-year data showing measurable vision gains and durable safety in small trials. But this remains investigational science, confined to registered clinical trials — there is no FDA-approved stem cell therapy for AMD, and real patients have been permanently blinded by unproven injections sold outside that research framework. Anyone interested in this approach should pursue it only through a verified clinical trial, never through a clinic offering direct-to-consumer “stem cell” eye injections.